麻豆精品一区二区三区蜜臀,污污网站18禁在线永久免费观看

首頁(yè)> 產(chǎn)品列表> 免疫學(xué)/炎癥程序性死亡-1抑制劑>

德瓦魯單抗

NMR下載 COA and HPLC MSDS下載
names：
Durvalumab
CAS號(hào)：
1428935-60-7
MDL Number：
MF(分子式)： C6502H10018N1742O2024S42 MW(分子量)： 146300.0 Da
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

德瓦魯單抗Durvalumab(1428935-60-7)是一種人免疫球蛋白G1κ（IgG1κ）單克隆抗體，德瓦魯單抗是一種用于癌癥治療的新型免疫檢查點(diǎn)抑制劑，durvalumab是重組DNA技術(shù)在中國(guó)倉(cāng)鼠卵巢（CHO）細(xì)胞懸浮培養(yǎng)物中生產(chǎn)的，是一種程序性死亡配體1（ PD-L1）阻斷抗體，可促進(jìn)攻擊腫瘤細(xì)胞的正常免疫反應(yīng)。

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫(kù)存描述	數(shù)量	總計(jì) (￥)
YZM004561-5mg	5mg	99%	￥ 5800.00	￥ 5800.00		2-3天	- +	￥ 0.00
YZM004561-1mg	1mg	99%	￥ 2650.00	￥ 2650.00		2-3天	- +	￥ 0.00

大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
收藏商品商品點(diǎn)評(píng) 加入購(gòu)物車立即購(gòu)買

快速詢價(jià)

收起

你想詢價(jià)的產(chǎn)品

*產(chǎn)品名稱：

CAS號(hào)：

產(chǎn)品編號(hào)：

需求描述：

請(qǐng)準(zhǔn)確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價(jià)

中文別名	德瓦魯單抗;Durvalumab(cas:1428935-60-7),度伐單抗,度伐魯單抗
英文別名	Durvalumab,1428935-60-7
CAS號(hào)	1428935-60-7
Inchi	1059477-92-7
InchiKey	1059477-92-7
分子式 Formula	C6502H10018N1742O2024S42
分子量 Molecular Weight	146300.0 Da
溶解度Solubility
性狀	Solid
儲(chǔ)藏條件 Storage conditions	請(qǐng)根據(jù)產(chǎn)品建議的存儲(chǔ)條件進(jìn)行存儲(chǔ),Please store the product under the recommended condition sin the description.

德瓦魯單抗Durvalumab(CAS:1428935-60-7)實(shí)驗(yàn)注意事項(xiàng)：
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲(chǔ)，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

產(chǎn)品說明	德瓦魯單抗(Durvalumab,MEDI 4736,1428935-60-7)是一種有效的人源化的抗PD-L1蛋白單克隆抗體
Introduction	Durvalumab (德瓦魯單抗,MEDI 4736,1428935-60) is an humanized antiD1monoclonal antibody.
Application1	Durvalumab (MEDI4736) completely blocks the binding of PD1to bothPDandCD80, withIC50s of 0.1 and 0.04 nM, respectively.
Application2	Durvalumab Half-life:Based on baseline clearance rate, the geometric mean terminal half-life is 18 days.
Application3

Durvalumab: Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner.

1、Keizer RJ, Huitema AD, Schellens JH, Beijnen JH: Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010 Aug;49(8):493-507. doi: 10.2165/11531280-000000000-00000. [PubMed:20608753]
2、Botticella A, Mezquita L, Le Pechoux C, Planchard D: Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619885530. doi: 10.1177/1753466619885530. [PubMed:31686616]
3、Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS: Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep. 2017 Jul 17;7(1):5532. doi: 10.1038/s41598-017-06002-8. [PubMed:28717238]
4、Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A: Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23;12:209-215. doi: 10.2147/DDDT.S141491. eCollection 2018. [PubMed:29416316]
Syed YY: Durvalumab: First Global Approval. Drugs. 2017 Aug;77(12):1369-1376. doi: 10.1007/s40265-017-0782-5. [PubMed:28643244]
5、Ni X, Song Q, Cassady K, Deng R, Jin H, Zhang M, Dong H, Forman S, Martin PJ, Chen YZ, Wang J, Zeng D: PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. J Clin Invest. 2017 May 1;127(5):1960-1977. doi: 10.1172/JCI91138. Epub 2017 Apr 17. [PubMed:28414296]
6、FDA Approved Drug Products: IMFINZI (durvalumab) injection, for intravenous use .
7、FDA.gov Resources for Information: FDA approves durvalumab for extensive-stage small cell lung cancer .
8、European Medicines Agency: IMFINZI (durvalumab) Summary of Product Characteristics.

警示圖
危險(xiǎn)性	warning
危險(xiǎn)性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對(duì)身體有害
安全防護(hù)	P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理
備注	實(shí)驗(yàn)過程中防止吸入、食入，做好安全防護(hù)